sST2 Predicts Short Term Therapy Success in Patients with Therapy Resistant Hypertension after Renal Sympathetic Denervation
Source abstract
Abstract
Background: Renal sympathetic denervation (RSD) has provided promising data in its ability to treat therapy resistant arterial hypertension. The effect of RSD on sST-2, a promising biomarker for risk stratification in cardiovascular diseases, has so far not been systematically studied. Methods: We evaluated serum levels of sST-2 and clinical parameter including left ventricular mass (LVM) in 54 patients with resistant hypertension (RH) undergoing bilateral RSD at baseline as well as at one and/or three months. Results: After RSD, mean office blood pressure showed a significant decrease after one month (p < 0.001). On echocardiography a reduction of LVM was observed at three months (p < 0.01). This was accompanied by a significant decrease of sST-2 levels at three months (sST-2 baseline: 6310.1 ± 3246.0 pg/mL vs. sST-2 three months: 4703.8 ± 1585.9 pg/mL, p = 0.048). Furthermore, baseline sST-2 levels were positively correlated with systolic blood pressure at one month (r = 0.514, p < 0.01) but not three months, indicating a potential predictive value of sST-2 for early intervention success. Conclusion: In patients with RH, RSD is associated with a significant decrease of sST-2 levels after three months, indicating sST-2 to be involved in remodeling processes after RSD. Furthermore, lower sST-2 levels at baseline might be a potential predictor of early intervention success of RSD.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Heart Rate Variability and Autonomic Control · Blood Pressure and Hypertension Studies · Hormonal Regulation and Hypertension
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Internal Medicine II, Paracelsus Medical University of Salzburg, 5020 Salzburg, Austria
Kardiologische Abteilung, Klinikum Wels-Grieskirchen, Grieskirchnerstrasse 42, 4600 Wels, Austria
Division of Cardiology, Hospital Maria Hilf Moenchengladbach, 41063 Moenchengladbach, Germany
Department of Cardiology I, Coronary and Peripheral Vascular Disease, Heart Failure, University Hospital Münster, Albert Schweitzer Campus 1, A1, 48149 Münster, Germany
References (36)
Show source-provided references
1. Resistant hypertension: Diagnosis, evaluation, and treatment: A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research10.1161/HYPERTENSIONAHA.108.189141 ↗
2. Renal sympathetic denervation for treatment of resistant hypertension: One year results from the Simplicity HTN-2 randomized controlled trial
3. A controlled trial of renal denervation for resistant hypertension10.1056/NEJMoa1402670 ↗
4. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-Month efficacy and safety results from the SPYRAL HTN-ON MED proof-Of-Concept randomised trial10.1016/S0140-6736(18)30951-6 ↗
5. Catheter-Based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): A randomised, sham–controlled, proof-Of-Concept trial10.1016/S0140-6736(17)32281-X ↗
6. Six-Month Results of Treatment-Blinded Medication Titration for Hypertension Control Following Randomization to Endovascular Ultrasound Renal Denervation or a Sham Procedure in the RADIANCE-HTN SOLO Trial10.1161/CIRCULATIONAHA.119.040451 ↗
7. 7. Brandt, M.C., Mahfoud, F., Reda, S., Schirmer, S.H., Erdmann, E., Bohm, M., and Hoppe, U.C. (2012). Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J. Am. Coll. Cardiol., 59, 901–909.10.1016/j.jacc.2011.11.034 ↗
8. Circulating biomarkers of hypertrophy and fibrosis in patients with hypertrophic cardiomyopathy assessed by cardiac magnetic resonance10.1080/1354750X.2018.1474261 ↗
9. sST2 as a value-Added biomarker in heart failure10.1016/j.cca.2019.10.029 ↗
10. Farcas, A.D., Anton, F.P., Goidescu, C.M., Gavrila, I.L., Vida-Simiti, L.A., and Stoia, M.A. (2017). Serum Soluble ST2 and Diastolic Dysfunction in Hypertensive Patients. Dis. Markers, 2714095.10.1155/2017/2714095 ↗
11. Recommendations for Chamber quantification: A report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology10.1016/j.echo.2005.10.005 ↗
12. The relationship of left ventricular mass and geometry to incident cardiovascular events: The MESA (Multi-Ethnic Study of Atherosclerosis) study10.1016/j.jacc.2008.09.014 ↗
13. Left ventricular hypertrophy increases cardiovascular risk independently of in-Office and out-Of-Office blood pressure values10.1097/HJH.0b013e328330b845 ↗
14. Regression of left ventricular mass by antihypertensive treatment: A meta-Analysis of randomized comparative studies10.1161/HYPERTENSIONAHA.109.136655 ↗
15. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies10.1093/ajh/5.2.95 ↗
16. A Three-Arm Randomized Trial of Different Renal Denervation Devices and Techniques in Patients with Resistant Hypertension (RADIOSOUND-HTN)10.1161/CIRCULATIONAHA.118.037654 ↗
17. Alcohol-Mediated Renal Denervation Using the Peregrine System Infusion Catheter for Treatment of Hypertension10.1016/j.jcin.2019.10.048 ↗
18. 2018 ESC/ESH Guidelines for the management of arterial hypertension10.1093/eurheartj/ehy339 ↗
19. Determinants of long-Term outcome in patients after percutaneous stent-Assisted intervention for renal artery steno-Occlusive atherosclerotic disease
20. Value of low dose combination treatment with blood pressure lowering drugs: Analysis of 354 randomised trials10.1136/bmj.326.7404.1427 ↗
21. Effect of renal denervation on left ventricular mass and function in patients with resistant hypertension: Data from a multi-Centre cardiovascular magnetic resonance imaging trial10.1093/eurheartj/ehu093 ↗
22. Improvements in left ventricular hypertrophy and diastolic function following renal denervation: Effects beyond blood pressure and heart rate reduction10.1016/j.jacc.2013.10.073 ↗
23. Reductions of left ventricular mass and atrial size following renal denervation: A meta–Analysis10.1007/s00392-016-0964-2 ↗
24. Effects of Renal Denervation on Cardiac Structural and Functional Abnormalities in Patients with Resistant Hypertension or Diastolic Dysfunction10.1038/s41598-017-18671-6 ↗
25. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-Resistant hypertension: Six-Month results from the prague-15 study10.1161/HYPERTENSIONAHA.114.04019 ↗
26. Renal denervation in heart failure with preserved ejection fraction (RDT-PEF): A randomized controlled trial10.1002/ejhf.502 ↗
27. Differences in left ventricular remodelling in patients with aortic stenosis treated with transcatheter aortic valve replacement with corevalve prostheses compared to surgery with porcine or bovine biological prostheses10.1093/ehjci/jew321 ↗
28. Aortic Stenosis, a Left Ventricular Disease: Insights from Advanced Imaging10.1007/s11886-016-0753-6 ↗
29. Left ventricular reverse remodeling after transcatheter aortic valve implantation: A cardiovascular magnetic resonance study10.1186/1532-429X-15-39 ↗
30. Soluble fms-Like tyrosine kinase-1 and endothelial adhesion molecules (intercellular cell adhesion molecule-1 and vascular cell adhesion molecule-1) as predictive markers for blood pressure reduction after renal sympathetic denervation10.1161/HYPERTENSIONAHA.113.02266 ↗
31. Circulating biomarkers in the early detection of hypertensive heart disease: Usefulness in the developing world10.21037/cdt.2019.09.10 ↗
32. Analytical and clinical evaluation of a novel high-Sensitivity assay for measurement of soluble ST2 in human plasma—The Presage ST2 assay10.1016/j.cca.2009.08.010 ↗
33. Reference value and clinical correlates of soluble ST2 in healthy community-Based Chinese population
34. Multi-Biomarker analysis in patients after transcatheter aortic valve implantation (TAVI)10.1080/1354750X.2018.1499127 ↗
35. Effects of renal sympathetic denervation on arterial stiffness and central hemodynamics in patients with resistant hypertension10.1016/j.jacc.2012.08.959 ↗
36. The Pressure Is On: Implications of Blood Pressure After Aortic Valve Replacement10.1161/JAHA.119.014631 ↗